Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 913-404-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
The oral LD50 was determined to be >2000 mg/kg bw.
The dermal LD50 was determined to be >2500 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- RCC Ltd. Toxicology Division, CH-4452 Itingen/Switzerland
- Test type:
- acute toxic class method
- Limit test:
- yes
- Specific details on test material used for the study:
- - Name of the test material: JODOSEPT L- Batch No. ZK 1055/175-2- ZHT no: 98/429-1- Storage: In the original container at room temperature, away from direct sunlight
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: RCC Ltd, Biotechnology & Animal Breeding Division, Wölferstrasse 4, CH-4414 Füllinsdorf/Switzerland- Age at study initiation: males 8 weeks, females 10 weeks- Weight at study initiation: males 209.5 – 220.5 g, females 167.9 – 182.8 g- Fasting period before study: overnight prior to intubation (approx. 17 h)- Housing: in groups of three in Makrolon type-4 cages with standard softwood bedding (“Lignocel”, Schill AG, CH-4132 Muttenz)- Diet: Pelleted standard Kliba 3433, batch no. 28/98, rat maintenance diet (Kliba Mühlen AG, CH-4301 Kaiseraugst) available ad libitum- Water: community tap water from Itingen, ad libitum ENVIRONMENTAL CONDITIONS - Temperature (°C): 22 ± 3 - Humidity (%): 40 - 70 - Air changes (per hr): 10 - 15 - Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- bi-distilled
- Details on oral exposure:
- VEHICLE - Concentration in vehicle: 20% (w/v) - Amount of vehicle (if gavage): 10 mL/kg bw
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 3
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days- Frequency of observations and check for viability: four times during test day 1 and once daily for surviving animals during days 2-15.- Frequency of weighing: On test day 1 (pre-administration), 8 and 15 for surviving animals.- Necropsy of survivors performed: yes- Other examinations performed: clinical signs were checked once daily.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths occured during the study.
- Clinical signs:
- No clinical signs were observed during the study period.
- Body weight:
- The body weight of the animals was within the range of physiological variability known for rats of this strain and age.
- Gross pathology:
- No macroscopic findings were observed at necropsy.
- Interpretation of results:
- GHS criteria not met
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Principles of method if other than guideline:
- Ten Sprague-Dawley rats per sex were exposed to 2500 mg/kg bw of the test substance for 24 hours. The substance was applied to the dorsal shaved skin. After an observation period of 14 days animals were necropsied.
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- - Name of the test material: PVP-Jod CE 5041- Purity: 92%
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: WIGA, Sulzfeld- Weight at study initiation: mean males 137 g, mean females 126 g- Diet: ad libitum, Altromin R (Altromin GmbH, Lage/Lippe)- Water: ad libitum
- Type of coverage:
- not specified
- Vehicle:
- water
- Details on dermal exposure:
- TEST SITE - Area of exposure: 50 cm2 shaved dorsal skin TEST MATERIAL- Concentration (if solution): 50%
- Duration of exposure:
- 24 hours
- Doses:
- 2500 mg/kg as 50% aq. solution
- No. of animals per sex per dose:
- 10
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days - Necropsy of survivors performed: yes- Other examinations performed: clinical signs and local irritation
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality was observed.
- Clinical signs:
- No clinical signs were observed.
- Gross pathology:
- The investigation revealed no pathological abnormalities.
- Other findings:
- No local signs of irritation were observed.
- Interpretation of results:
- GHS criteria not met
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 500 mg/kg bw
Additional information
Acute oral toxicity
There are seven acute toxicity studies available, which are all performed with rats.
In a GLP compliant study (1999), performed according to OECD guideline 423, three Wistar rats per sex were exposed to the test substance via oral gavage. The animals were exposed to 2000 mg/kg bw dissolved in water. After an observation period of 14 days animals were necropsied. No mortality was observed. No clinical signs or macroscopic findings during necropsy were observed. The body weight of the animals was within the range of physiological variability. The LD50 was determined to be >2000 mg/kg bw.
In a second study (1977) ten Sprague-Dawley rats per sex per dose were exposed to the test substance via oral gavage. Animals were exposed to 3830, 4640, 5620 or 6810 mg/kg bw dissolved in water. After an observation period of 14 days animals were necropsied. Diarrhea, dyspnea, apathy, brown colored feces and urine, a poor general state, staggering, and a spastic gait were observed. Upon necropsy in the animals that died acute dilatation and congestive hyperemia of the heart was observed. Liver consisted of broadened peripheral lobules, was general yellowish discolored and of soft consistence indicating degeneration. Also atonic bowels, containing diarrhea were observed. No gross pathology effects were observed in the sacrificed animals. The LD50 was determined to be 6800, 4600 - 5600, and 5990 mg/kg bw, for males, females and males/females, respectively.
In a third study (1977) ten Sprague-Dawley rats per sex per dose were exposed to the test substance via oral gavage. Animals were exposed to 4640, 5620, 6810, 8250 or 10000 mg/kg bw dissolved in water. After an observation period of 14 days animals were necropsied. Symptoms observed included dyspnea, apathy, diarrhea, tumbling, spastic gait, red discoloration of the skin, slight exsiccation and partly poor general state. In animals that died during the experiment diffuse redness of the glandular stomach, diarrhetic contents in the bowel, acute dilatation and congestive hyperemia of the heart, broadened peripherical lobules and grey discoloration of the liver, and sometimes hydrothorax were observed upon necropsy. No pathological abnormalities were observed in the sacrificed animals. The LD50 was determined to be 7220, 6970, and 7090 mg/kg bw for males, females, and males/females, respectively.
In a fourth study (1977) ten Sprague-Dawley rats per sex per dose were exposed to the test substance via oral gavage. Animals were exposed to 3160, 3830, 4640, 5620, 6810 mg/kg bw dissolved in water. After an observation period of 14 days animals were necropsied. Symptoms observed included dyspnea, diarrhea and brownish feces, increasing apathy and tumbling, convulsions, brownish urine, abdominal side position and exsiccation. In animals that died pathological investigation showed acute dilatation and congestive hyperemia of the heart, broadened peripherical lobules and grey discoloration of the liver that became soft (indicating degeneration), ulceration of the stomach, and bloody and diarrhetic contents of the bowel. No pathological abnormalities were observed upon necropsy of the sacrificed animals. The LD50 was determined to be 4930, 4070, and 4470 mg/kg bw for males, females, and males/females, respectively.
In a fifth study (1985) five Wistar rats per sex per dose were exposed to the test substance via oral gavage. Animals were exposed to 2610, 3830 or 5000 mg/kg bw dissolved in olive oil. After an observation period of 14 days animals were necropsied. One male and one female of the highest dose group died. No mortality observed in any of the other tested groups. Clinical symptoms were observed in highest dose group and included dyspnea, apathy, staggering, piloerection and a poor general state (symptom-free after 2 days). No abnormalities were detected upon necropsy in the sacrificed animals and in the female that died during the study. Diagnosis was not possible for the male that died because of autolysis. The LD50 was determined to be >5000 mg/kg bw for both males and females.
In the sixth study (1979) Sprague-Dawley rats were exposed to the test substances via oral gavage. Ten males per dose were exposed to 4680 or 6810 mg/kg bw. Ten females per dose were exposed to 3160, 4640 or 6810 mg/kg bw, and an additional 5 females were exposed to 1000 mg/kg bw. Animals were observed for 14 days. Ruffled fur, incoordination and tremor observed in animals exposed to 6810 mg/kg bw. The LD50 was determined to be 5695.37 and >6810 mg/kg bw for females and males, respectively.
In the seventh study (1979) ten male Wistar rats per dose were exposed to the test substance via oral gavage. After an observation period of 14 days animals were necropsied. Light, moderate or strong sedation and a ruffled fur were observed. Strong gas accumulations were observed in the stomach and intestinal tract, in animals that died and sacrificed animals. Additionally, intestinal inflammation was observed in animals exposed to high concentrations. The LD50 was determined to be 6420 mg/kg bw.
Acute dermal toxicity
Ten Sprague-Dawley rats per sex were exposed to 2500 mg/kg bw of the test substance for 24 hours. The substance was applied to the dorsal shaved skin. After an observation period of 14 days animals were necropsied. No mortality was observed. No clinical signs or pathological abnormalities upon necropsy were observed. The LD50 was determined to be >2500 mg/kg bw for both males and females.
Justification for classification or non-classification
As the oral LD50 was determined to be >2000 mg/kg bw and the dermal LD50 was determined to be >2500 mg/kg bw, classification for oral and dermal acute toxicity is not warranted in accordance with EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation No. 1272/2008.
Based on the available information classification for acute inhalation toxicity is not possible in accordance with EU Classification, Labeling and Packaging of Substances and Mixtures (CLP) Regulation No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
